US30985A - Thomas l - Google Patents

Thomas l Download PDF

Info

Publication number
US30985A
US30985A US30985DA US30985A US 30985 A US30985 A US 30985A US 30985D A US30985D A US 30985DA US 30985 A US30985 A US 30985A
Authority
US
United States
Prior art keywords
bracket
socket
rod
thomas
pipe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US30985A publication Critical patent/US30985A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A47FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47HFURNISHINGS FOR WINDOWS OR DOORS
    • A47H5/00Devices for drawing draperies, curtains, or the like
    • A47H5/02Devices for opening and closing curtains
    • A47H5/032Devices with guiding means and draw cords
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16HGEARING
    • F16H7/00Gearings for conveying rotary motion by endless flexible members
    • F16H7/08Means for varying tension of belts, ropes, or chains
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16HGEARING
    • F16H7/00Gearings for conveying rotary motion by endless flexible members
    • F16H7/08Means for varying tension of belts, ropes, or chains
    • F16H2007/0889Path of movement of the finally actuated member
    • F16H2007/0891Linear path

Definitions

  • My said invention relates to the bracket carrying the sheave or roller around which the cord to the window shade or curtain passes, and which bracket keeps said cord tight.
  • c is the curtain cord passing around the roller or sheave d
  • e is a wire or rod carrying this roller d, which rod may be either square round or oval in section and passes through the spring clamp f, that is formed as a split pipe to receive the said rod e, and is clamped upon the surface of said rod by the socket g, so that the rod is held firmly at any point to which it may be drawn or slid in the act of tighteningthe cord c.
  • the socket g is made tapering so as to force the divided or split pipe f firmly upon the surface of the rod e, as the said socket is made to act upon the said pipe, and for this purpose smooth tapering surfaces in the inside of said socket and outside of the pipe may be used as in F ig.
  • a conical or tapering screw thread may be provided as in Fig. 2. It will be seen that in Fig. 1, the split pipe f is attached to or formed on the screw bracket o, while the socket g is movable, but that in Fig. 2, the socket g is on the bracket b, and the pipe 7" is movable; the action in both cases being the same.
  • Vhat I claim and desire to secure by Iletters Patent is The divided or split pipe f, and tapering socket g, combined with the rod c, carrying the roller d, substantially as specified.

Landscapes

  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Curtains And Furnishings For Windows Or Doors (AREA)

Description

UNITED STATES PATENT OFFICE.
THOMAS L. PYE, OF NEWY YORK, N. Y.
BRACKET FOR CURTAIN-CORDS.
Specification of Letters Patent No. 30,985, dated December 18, 1860. i
To all whom t may concern:
Be it known that I, THOMAS L. PYE, of the city and State of New York, have invented, made, and applied to use a certain new and useful Improvement in Brackets for the Cords of Curtains; and I do hereby declare that the following' is a full, clear, and exact description of the nature of my said invention, reference being had to the annexed drawing, making part of this specification, wherein- Figure 1 is a vertical section of my said bracket, and Fig. 2 is an elevation of the same in a slightly modified form.
Similar marks of reference denote the same parts.
My said invention relates to the bracket carrying the sheave or roller around which the cord to the window shade or curtain passes, and which bracket keeps said cord tight.
In the drawing a, is a portion of the window casing or other surface to which the bracket is attached by the screw bracket o.
c, is the curtain cord passing around the roller or sheave d, and e, is a wire or rod carrying this roller d, which rod may be either square round or oval in section and passes through the spring clamp f, that is formed as a split pipe to receive the said rod e, and is clamped upon the surface of said rod by the socket g, so that the rod is held firmly at any point to which it may be drawn or slid in the act of tighteningthe cord c. The socket g is made tapering so as to force the divided or split pipe f firmly upon the surface of the rod e, as the said socket is made to act upon the said pipe, and for this purpose smooth tapering surfaces in the inside of said socket and outside of the pipe may be used as in F ig. l, or a conical or tapering screw thread may be provided as in Fig. 2. It will be seen that in Fig. 1, the split pipe f is attached to or formed on the screw bracket o, while the socket g is movable, but that in Fig. 2, the socket g is on the bracket b, and the pipe 7" is movable; the action in both cases being the same.
Vhat I claim and desire to secure by Iletters Patent is The divided or split pipe f, and tapering socket g, combined with the rod c, carrying the roller d, substantially as specified.
In witness whereof I have hereunto set my signature this thirtieth day of Novem- 2 ber 1860.
THOS. L. PYE. Witnesses:
CHAs. H. SMITH, THos. GEO. HAROLD.
US30985D Thomas l Expired - Lifetime US30985A (en)

Publications (1)

Publication Number Publication Date
US30985A true US30985A (en) 1860-12-18

Family

ID=2100622

Family Applications (1)

Application Number Title Priority Date Filing Date
US30985D Expired - Lifetime US30985A (en) Thomas l

Country Status (1)

Country Link
US (1) US30985A (en)

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
WO1986000335A1 (en) * 1984-06-22 1986-01-16 Veech Richard L Electrolyte solutions and in vitro use thereof
US4615977A (en) * 1981-12-24 1986-10-07 Asahi Kasei Kogyo Kabushiki Kaisha Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4663289A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vitro use thereof
US4757018A (en) * 1985-02-11 1988-07-12 Hazleton Biotechnologies, Inc. Myeloma cell lines and uses thereof
US4786599A (en) * 1983-03-24 1988-11-22 Institut National De La Sante Et De La Recherche Medicale Serum-free animal cell culture medium and methods for the primary culture and production of cell lines using this medium
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US20030087372A1 (en) * 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US20040005603A1 (en) * 2002-04-10 2004-01-08 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20050149994A1 (en) * 2001-12-19 2005-07-07 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
US20080233118A1 (en) * 2005-07-28 2008-09-25 Novartis Ag Uses Of Antibody To M-Csf
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US20100092464A1 (en) * 2005-07-28 2010-04-15 Novartis Ag M-CSF-Specific Monoclonal Antibody and Uses Thereof
WO2010048446A2 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2494988A1 (en) 2006-12-07 2012-09-05 Novartis AG Antagonist antibodies against EPHB3
WO2012167143A1 (en) 2011-06-03 2012-12-06 Xoma Technology Ltd. Antibodies specific for tgf-beta
WO2013090915A1 (en) 2011-12-16 2013-06-20 Braskem S.A. Modified microorganisms and methods of making butadiene using same
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US8586716B2 (en) 2006-08-04 2013-11-19 Novartis Ag EPHB3-specific antibody and uses thereof
US9005614B2 (en) 2006-08-18 2015-04-14 Novartis Ag PRLR-specific antibody and uses thereof
WO2015184327A1 (en) 2014-05-30 2015-12-03 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
WO2016061240A1 (en) 2014-10-15 2016-04-21 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
WO2016061141A1 (en) 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
EP3385279A1 (en) 2009-03-20 2018-10-10 Amgen Inc. Carrier immunoglobulins and uses thereof
EP3415528A2 (en) 2011-04-13 2018-12-19 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EP3453724A1 (en) 2006-04-24 2019-03-13 Amgen Inc. Humanized c-kit antibody
EP3476861A1 (en) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
EP3536799A2 (en) 2013-09-23 2019-09-11 Braskem S.A. Engineered enzyme having acetoacetyl-coa hydrolase activity, microorganisms comprising same, and methods of using same
WO2020032444A1 (en) 2018-08-07 2020-02-13 (주)휴온스 METHOD FOR PREPARING GLY-Tβ4
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
WO2020168315A1 (en) 2019-02-15 2020-08-20 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
EP3699269A1 (en) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression of fc-containing proteins
WO2020213724A1 (en) 2019-04-19 2020-10-22 中外製薬株式会社 Chimeric receptor recognizing modification site of antibody
WO2020243477A2 (en) 2019-05-30 2020-12-03 Amgen Inc. Engineering the hinge region to drive antibody dimerization
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
WO2021010326A1 (en) 2019-07-12 2021-01-21 中外製薬株式会社 Anti-mutation type fgfr3 antibody and use therefor
WO2021014389A1 (en) 2019-07-24 2021-01-28 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof
US10981995B2 (en) 2015-08-06 2021-04-20 Wuxi Biologies Ireland Limited Anti-PD-L1 antibodies
WO2021102049A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
WO2021127528A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
US11046987B2 (en) 2010-05-28 2021-06-29 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2022165001A1 (en) 2021-01-29 2022-08-04 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2022225921A1 (en) 2021-04-20 2022-10-27 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
WO2023154305A2 (en) 2022-02-10 2023-08-17 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing
WO2023172965A1 (en) 2022-03-09 2023-09-14 Amgen Inc. Optimized transfection protocol
WO2023172903A1 (en) 2022-03-08 2023-09-14 Amgen Inc. Modular vector (modvec) system: a platform for construction of next generation expression vectors
EP4282877A2 (en) 2015-08-11 2023-11-29 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
EP4331604A2 (en) 2008-12-09 2024-03-06 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615977A (en) * 1981-12-24 1986-10-07 Asahi Kasei Kogyo Kabushiki Kaisha Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4786599A (en) * 1983-03-24 1988-11-22 Institut National De La Sante Et De La Recherche Medicale Serum-free animal cell culture medium and methods for the primary culture and production of cell lines using this medium
WO1986000335A1 (en) * 1984-06-22 1986-01-16 Veech Richard L Electrolyte solutions and in vitro use thereof
US4663289A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vitro use thereof
US4757018A (en) * 1985-02-11 1988-07-12 Hazleton Biotechnologies, Inc. Myeloma cell lines and uses thereof
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
EP0380495B1 (en) * 1987-07-24 1994-05-18 Cetus Oncology Corporation Serum free media for the growth of insect cells and expression of products thereby
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US20030087372A1 (en) * 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US20050149994A1 (en) * 2001-12-19 2005-07-07 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
US20040005603A1 (en) * 2002-04-10 2004-01-08 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP3476861A1 (en) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
US20080233118A1 (en) * 2005-07-28 2008-09-25 Novartis Ag Uses Of Antibody To M-Csf
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
US20100092464A1 (en) * 2005-07-28 2010-04-15 Novartis Ag M-CSF-Specific Monoclonal Antibody and Uses Thereof
EP3453724A1 (en) 2006-04-24 2019-03-13 Amgen Inc. Humanized c-kit antibody
US9006398B2 (en) 2006-08-04 2015-04-14 Novartis Ag EPHB3-specific antibody and uses thereof
US8586716B2 (en) 2006-08-04 2013-11-19 Novartis Ag EPHB3-specific antibody and uses thereof
EP3415532A1 (en) 2006-08-18 2018-12-19 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
EP3018144A1 (en) 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
US9005614B2 (en) 2006-08-18 2015-04-14 Novartis Ag PRLR-specific antibody and uses thereof
EP2494988A1 (en) 2006-12-07 2012-09-05 Novartis AG Antagonist antibodies against EPHB3
EP2261254A2 (en) 2007-12-21 2010-12-15 Amgen, Inc Anti-amyloid antibodies and uses thereof
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2010048446A2 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
EP4331604A2 (en) 2008-12-09 2024-03-06 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3385279A1 (en) 2009-03-20 2018-10-10 Amgen Inc. Carrier immunoglobulins and uses thereof
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
US11046987B2 (en) 2010-05-28 2021-06-29 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP3415528A2 (en) 2011-04-13 2018-12-19 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012167143A1 (en) 2011-06-03 2012-12-06 Xoma Technology Ltd. Antibodies specific for tgf-beta
EP3954704A1 (en) 2011-06-03 2022-02-16 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2013090915A1 (en) 2011-12-16 2013-06-20 Braskem S.A. Modified microorganisms and methods of making butadiene using same
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP3536799A2 (en) 2013-09-23 2019-09-11 Braskem S.A. Engineered enzyme having acetoacetyl-coa hydrolase activity, microorganisms comprising same, and methods of using same
WO2015184327A1 (en) 2014-05-30 2015-12-03 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
WO2016061141A1 (en) 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
WO2016061240A1 (en) 2014-10-15 2016-04-21 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
EP3722433A1 (en) 2014-10-15 2020-10-14 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
US10981995B2 (en) 2015-08-06 2021-04-20 Wuxi Biologies Ireland Limited Anti-PD-L1 antibodies
EP4282877A2 (en) 2015-08-11 2023-11-29 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
EP3699269A1 (en) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression of fc-containing proteins
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
EP3925970A1 (en) 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
WO2020032444A1 (en) 2018-08-07 2020-02-13 (주)휴온스 METHOD FOR PREPARING GLY-Tβ4
WO2020168315A1 (en) 2019-02-15 2020-08-20 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
WO2020213724A1 (en) 2019-04-19 2020-10-22 中外製薬株式会社 Chimeric receptor recognizing modification site of antibody
WO2020243477A2 (en) 2019-05-30 2020-12-03 Amgen Inc. Engineering the hinge region to drive antibody dimerization
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
WO2021010326A1 (en) 2019-07-12 2021-01-21 中外製薬株式会社 Anti-mutation type fgfr3 antibody and use therefor
WO2021014389A1 (en) 2019-07-24 2021-01-28 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof
WO2021102049A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
WO2021127528A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2022165001A1 (en) 2021-01-29 2022-08-04 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
US12110330B2 (en) 2021-01-29 2024-10-08 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof
WO2022225921A1 (en) 2021-04-20 2022-10-27 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
WO2023154305A2 (en) 2022-02-10 2023-08-17 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing
WO2023172903A1 (en) 2022-03-08 2023-09-14 Amgen Inc. Modular vector (modvec) system: a platform for construction of next generation expression vectors
WO2023172965A1 (en) 2022-03-09 2023-09-14 Amgen Inc. Optimized transfection protocol

Similar Documents

Publication Publication Date Title
US30985A (en) Thomas l
US262398A (en) gxraed
US74489A (en) Improvement in wood-soeews
US32034A (en) Langdon sawyer
US26839A (en) Valorus drew
US904229A (en) Portiere-rod.
US27410A (en) Geoft
US27473A (en) Window-screen
US1202475A (en) Tent-supporter.
US30172A (en) whitwell
US35355A (en) Improvement in the means of attaching india-rubber to pencils
US19226A (en) Asmhinor to john
US1202287A (en) Shade-roller.
US31550A (en) Joseph y
US20013A (en) Ctrataiet-fixttjre
US1051192A (en) Adjustable window-shade carrier.
US84824A (en) hemingway
US375986A (en) Spring shade-roller
US38245A (en) Improved rubber spring
US639439A (en) Shade and curtain bracket.
US31643A (en) Bons l
US462359A (en) Charles a
US26824A (en) Improved curtain-fixture
US98384A (en) Improved curtain-fixture
US40466A (en) Improved curtain-fixture